Tumor plasticity in the translational space Pierre Saintigny Centre Léon Bérard Centre de Recherche en Cancérologie de Lyon Université de Lyon Forum de la Recherche en Cancérologie Vendredi 5 Avril 2019 LYon Recherche Innovation contre le CANcer INCa-DGOS-Inserm_12563
21
Embed
Tumor plasticity in the translational space · Drug/Tool Tumor characterization Patients stratification Innovative clinical trials IRP1 IRP2 IRP3 PLASTICITY 1 2 4 3 5. ... OVERCOMING
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Tumor plasticity in the translational space
Pierre Saintigny
Centre Léon Bérard
Centre de Recherche en Cancérologie de Lyon
Université de Lyon
Forum de la Recherche en CancérologieVendredi 5 Avril 2019
LYon Recherche Innovation
contre le CANcer
INCa-DGOS-Inserm_12563
LYriCAN : OBJECTIVES AND AMBITION
Address a next set of questions in molecular medicine
Pursue our strategy of identification of novel nosological entities
Describe the multidimensional complexity of cancer
Develop first-in-human, combination Phase 1 studies, randomized Phase II trials, basket & umbrella studies, and Phase III trials within national/international networks
Develop innovative physical and mathematical methods to analyze and treattumor plasticity at the macroscopic level
Integrate Social Sciences and Humanities
Develop innovative training programs
Build multidisciplinary partnerships to promote intellectual property protection, spin off creation and transfer of innovation to patient care
Characterize and treat cancer and immune cell plasticity through coordinated approaches
Development of paradigm changing for local and systemic cancer therapies
Innovative diagnostic tools
FROM LYric TO LYriCAN
Cancer cellsand immune
targets
Combining treatments to
prevent resistance
Physical Agents
Overcomingcell
plasticity
Tumorcell
Macro-scopictumor
Immunotherapy
New targetsand
treatments
Personalised medicinebased on genomic
context
DevWeCan, PlasCan
TumAdoR, Hermione2Man
Personalized medicine based on genomic context and
tumoral heterogeneity
AURAGEN, EURACAN, SSH Chair
ProfiLERMOST
BASIC RESEARCH
LYriCAN AND PARTNERS
GCS-LCU
New Partner
PARTNERS
• SCIENTIFIC DIRECTION
Jean-Yves BLAY• COORDINATION
Marina Rousseau-Tsangaris
STRONG BASIC RESEARCH
MULTIDISCIPLINARITY
RESEARCH ENTITIES
CRCL - LABTAU
CREATIS
UNIVERSITY HOSPITALS
HUMAN AND SOCIAL SCIENCES
TRIANGLE
BIOINFORMATICS
APPLIED MATHEMATICS
ALGORITHMS
DIGITAL HEALTH
EPIDEMIOLOGY
PREVENTION
COHORTS
CLINICAL RESEARCH
TRAINING
EDUCATION
MASTERS
TECHNOLOGICAL PLATFORMS
MANIPULATING CELL PLASTICITY FOR INNOVATIVE CANCER TREATMENT
BASIC RESEARCH
CLINICAL RESEARCH
Mechanism
IdentifyDrug/Tool
Tumor characterization
Patients stratification
Innovativeclinical trials
IRP1
IRP3IRP2PLASTICITY
1
2
34
5
TUMOR MODELS
OVERCOMINGCANCER CELL PLASTICITY
INTRA-TUMORAL HETEROGENEITY
Genetic alteration
Epigenetic modification
Micro-environment Cancer cellCancer Stem cell
PrimaryResistance
SecondaryResistance
Targeted therapyImmunotherapy
Conventional TherapyTreatment combination
Targeted therapyImmunotherapy
Conventional TherapyTreatment combination
Normal cell
Improve treatments – Response prediction
UNDERSTANDING CELL PLASTICITY TO IDENTIFY INNOVATIVE CANCER CELL AND IMMUNE TARGETSIRP1
COMBINING TREATMENTS TO PREVENT PRIMARY AND SECONDARY RESISTANCE THROUGH CANCER CELL PLASTICITY
IRP2
PHYSICAL AND MATHEMATICAL METHODS TO ANALYZE AND OVERCOME TUMOR PLASTICITY AT THE MACROSCOPIC LEVEL FOR PERSONALIZED TREATMENTSIRP3
Lung tumors MelanomaPancreatic tumors
Rare tumorsGIST Sarcoma Neuroendocrine tumors Ovarian tumors Head and Neck tumors
Breast tumorsLymphoma
Prevention - Prediction
Pediatric tumors
UNDERSTANDING CELL PLASTICITY TO IDENTIFY INNOVATIVE CANCER CELL AND IMMUNE TARGETS
INTEGRATED RESEARCH PROGRAM 1
Leaders : A Traverse-Glehen - C Caux – Young Faculty : N Bendriss-Vermare
v
Cancer and immune cell
plasticity
Genetic drivers and epigeneticreprogramming
EMT targeting
Axis 1
Axis 3 Axis 4
Axis 2
Cell plasticityand Immune
responses
Patient trajectories,
networks, accessto treatments
INTEGRATED RESEARCH PROGRAM 1UNDERSTANDING CELL PLASTICITY TO IDENTIFY INNOVATIVE CANCER CELL AND IMMUNE TARGETS
COMBINING TREATMENTS TO PREVENT PRIMARY AND SECONDARY RESISTANCE THROUGH CANCER CELL PLASTICITY
INTEGRATED RESEARCH PROGRAM 2
Leaders: P Saintigny - S Dalle – Young Faculty : A Dufresne
v
Resistance to targetedtherapy
Resistance to immune therapy
Innovative combination treatment
Hospitalorganization
Self reportingtools
Big data visualization
Axis 1
Axis 3
Axis 4
Axis 2
Cancer cell
plasticity
INTEGRATED RESEARCH PROGRAM 2COMBINING TREATMENTS
PHYSICAL AND MATHEMATICAL METHODS TO ANALYZE AND OVERCOME TUMOR PLASTICITY AT THE MACROSCOPIC LEVEL FOR PERSONALIZED TREATMENTS
INTEGRATED RESEARCH PROGRAM 3
Leaders: AL Giraudet - D Sarrut – Young Faculty : A Dupré
2. Imaging tumorplasticity
Tools:Conventional imaging and Radiomic (Axis 3)Immunoscintigraphy (Axis 2 and 3)Dosimetry (Axis 2)